Építés alatt – nem éles oldal
Belépés
Befejeződött1. fázis

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

A legfontosabb adatok

Ki végzi
Suzhou Zanrong Pharma Limited
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
1. fázis
Résztvevők
61 fő vett részt
Kezdés
2020. okt. 15.
Befejezés
2025. ápr. 16.
A vizsgálat típusa
Beavatkozással járó, 11 csoport
A vizsgált kezelések
  • ZN-A-1041 50mg BID
  • ZN-A-1041 100mg BID
  • ZN-A-1041 200mg BID
  • ZN-A-1041 400mg BID
  • ZN-A-1041 600mg BID
  • ZN-A-1041 800mg BID
  • ZN-A-1041 1000mg BID
  • ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
  • ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
  • ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First Cycle
  • ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle
A regiszteradat frissítve
2025. augusztus 11.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt
A regiszter összes feltétele (22)A regiszter feltételeinek elrejtése

Ki vehet részt

  • ECOG performance status of 0 to 1 2. HER2-positive is defined as Immunohistochemistry (IHC) (++) and Fluorescence In Situ Hybridization (FISH) positive, or IHC (+++)
  • Phase 1a study will enroll patients with unresectable or metastatic HER2-positive advanced solid tumor; Phase 1b study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer
  • For patients who have no brain metastases, the following criteria should be met:
  • Patients should be relapsed or refractory to existing therapy(ies) or have been intolerant of such therapies
  • Have at least one extracranial measurable lesion by RECIST v1. 1 ii. For patients with brain metastasis, the following criteria should be met:
  • Have received prior treatment or patient declined the above treatment; 2) Patients with HER2-positive gastric cancer must have previously received Trastuzumab 3) Do not require immediate local treatment during the trial period, and meet either of the following two criteria:
  • For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT and 2 weeks from SRS
  • Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period
  • In Phase 1a, for patients who have received previous tyrosine kinase inhibitor (TKI) treatment, chemotherapy, antibody, or antibody-drug conjugate (ADC), the interval between the last treatment and the first administration of the study drug in this trial should be at least 2 weeks. In Phase 1b, for patients who have received previous trastuzumab or other antibodies, the interval between the last treatment and the first administration of the study drug in this trial should be at least 3 weeks
  • Phase 1c study will enroll patients with unresectable locally-advanced or metastatic HER2+ breast cancer with brain metastases
  • For patients with brain metastasis, patients do not require immediate local treatment during the trial period, and meet either of the following two criteria:
  • For patients who have received previous local treatment (surgery, whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS)) for brain metastases, stable or progression of intracranial lesions is required. Interval from prior local therapy could be 3 weeks from WBRT, 2 weeks from SRS and 4 weeks from surgery
  • Symptomatic or not, patient has not received previous local treatment (surgery or radiotherapy) for brain metastases as long as no local therapy is needed during the trial period
  • Have at least one measurable lesion and is suitable for accurate repeated assessable by RECIST 1.1, and the patient has an imaging-diagnosable intracranial lesion
  • Patients should not include suspected or confirmed meningeal metastases
  • The patient had no disease progression with previous 12 weeks' capecitabine therapy
  • No capecitabine therapy within 6 months
  • Patient should not previously treat with a tyrosine kinase inhibitor (TKI). Previous treatment with trastuzumab or other antibodies should be at least 3 weeks apart from the first treatment

Ki nem vehet részt

  • Subjects who have participated in any clinical study or received any clinical study drug within 4 weeks prior to the first administration
  • Previous cumulative dose of doxorubicin exceeds 360mg/m2 or its equivalent dose of similar drugs
  • CNS Exclusion - Based on screening brain MRI and clinical assessment; Progressive neurologic impairment or increased intracranial pressure (including nausea, vomiting, blurred vision, headache, epilepsy, etc.); Any intracranial lesion thought to require immediate local therapy; Require antiepileptic treatment (except for these patients with stable seizures require continuous Levetiracetam therapy); Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)
  • There is evidence that other primary tumors are present at the same time

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors.

A teljes eredeti leírásKevesebb

The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).

A vizsgálat 11 csoportja

  • ZN-A-1041 50mgA vizsgált kezelés

    Phase 1a: Subjects will be given ZN-A-1041 orally 50mg Bid, for 21days as one cycle

    Kezelés: ZN-A-1041 50mg BID

  • ZN-A-1041 100mgA vizsgált kezelés

    Phase 1a: Subjects will be given ZN-A-1041 orally 100mg Bid, for 21days as one cycle

    Kezelés: ZN-A-1041 100mg BID

  • ZN-A-1041 200mgA vizsgált kezelés

    Phase 1a: Subjects will be given ZN-A-1041 orally 200mg Bid, for 21days as one cycle

    Kezelés: ZN-A-1041 200mg BID

  • ZN-A-1041 400mgA vizsgált kezelés

    Phase 1a: Subjects will be given ZN-A-1041 orally 400mg Bid, for 21days as one cycle

    Kezelés: ZN-A-1041 400mg BID

  • ZN-A-1041 600mgA vizsgált kezelés

    Phase 1a: Subjects will be given ZN-A-1041 orally 600mg Bid, for 21days as one cycle

    Kezelés: ZN-A-1041 600mg BID

  • ZN-A-1041 800mgA vizsgált kezelés

    Phase 1a: Subjects will be given ZN-A-1041 orally 800mg Bid, for 21days as one cycle

    Kezelés: ZN-A-1041 800mg BID

  • ZN-A-1041 1000mgA vizsgált kezelés

    Phase 1a: Subjects will be given ZN-A-1041 orally 1000mg Bid, for 21days as one cycle

    Kezelés: ZN-A-1041 1000mg BID

  • ZN-A-1041 level 1+Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First CycleA vizsgált kezelés

    Phase 1b: ZN-A-1041 Level 1 (The previous dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study. Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle. Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

  • ZN-A-1041 level 2+Capecitabine 1000 mg/m2+ Trastuzumab 8 mg/kg iv. First CycleA vizsgált kezelés

    Phase 1b: ZN-A-1041 Level 2 ( dose of MTD) to be used in the combination therapy will be determined based on the MTD identified in the Phase 1a study. Capecitabine will be given at the dose of 1000 mg/m2, BID (2000 mg/m2/day), during the first 2 weeks of the 21-day treatment cycle. Trastuzumab (8 mg/kg in cycle 1 followed by 6 mg/kg beginning in cycle 2, administered as an IV infusion. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

  • ZN-A-1041 MAD+Capecitabine 1000 mg/m2+Trastuzumab 8 mg/kg iv. First CycleA vizsgált kezelés

    Phase 1b: If the MTD is still not reached at the maximum dose level in Phase 1a study, the maximum dose level (MAD) of ZN-A-1041 in Phase 1a will be used in Phase 1b study. If intolerance, reduce Capecitabine dose to 750 mg/m2 for exploration

  • ZN-A-1041+Capecitabine+TrastuzumabA vizsgált kezelés

    Phase 1c: The combined dose of ZN-A-1041 is based on the recommended combined dose in the Phase 1b and the possible changes in the dosage form and the results of the food effect study, which will be decided by the sponsor and the investigator after discussion

    Kezelés: ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First Cycle

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors
A regiszteradat frissítve
2025. augusztus 11.